Key result
ACE inhibitors and ARBs were associated with a decreased risk of cancer development compared with controls (HR 0.51, 95% CI 0.39-0.68 for ACE inhibitors; HR 0.8, 95% CI 0.65-0.97 for ARBs).
Why the study?
Does the use of ACE inhibitors or ARBs affect the risk of cancer development in patients with essential hypertension?
Population
297,688 patients with essential hypertension from the Taiwan National Health Insurance Research Database
Comparison
Angiotensin-converting enzyme inhibitors or… vs Control group
Design
Cohort
Authors
Loading...
Should not yet change prescribing in hypertension; hypothesis-generating for lower cancer risk with ACE inhibitors or ARBs and needs randomized confirmation.
Cohort (n=297,688)
Does the use of ACE inhibitors or ARBs affect the risk of cancer development in patients with essential hypertension?
Hazard Ratio: 0.51 (95% CI 0.39–0.68)
In a large population-based cohort, regular use of ACE inhibitors or ARBs for essential hypertension was associated with a significantly lower risk of developing cancer compared to other antihypertensive therapies.
Chiang et al. (2013) conducted a cohort in essential hypertension (n=297,688). ACE inhibitors/ARBs vs. control group was evaluated on occurrence of cancer (HR 0.51, 95% CI 0.39-0.68). ACE inhibitors and ARBs were associated with a decreased risk of cancer development compared with controls (HR 0.51, 95% CI 0.39-0.68 for ACE inhibitors; HR 0.8, 95% CI 0.65-0.97 for ARBs).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: